Profiling the expression of cytochrome P450 in breast cancer

Graeme I Murray, Siva Patimalla, Keith N Stewart, Iain D Miller, Steve D Heys

Research output: Contribution to journalArticlepeer-review

129 Citations (Scopus)


The cytochrome P450s are key oxidative enzymes which metabolise of carcinogens and anti-cancer drugs. Thus these enzymes influence tumour development, tumour response to therapy and are putative tumour biomarkers. The purpose of this study was to define the cytochrome P450 expression profile in breast cancer and establish the significance of cytochrome P450 expression in this tumour type.
Methods and results
A tissue microarray containing 170 breast cancers of no special type was immunostained for a panel of 21 cytochrome P450s. The highest percentage of strongly positive staining in breast cancers was seen for CYP4X1 (50.8%), CYP2S1 (37.5%) and CYP2U1 (32.2%) respectively, while CYP2J (98.6%) and CYP3A43 (70.7%) were the cytochrome P450s that most frequently displayed no immunoreactivity respectively. CYP4V2 (p=0.01), CYP4X1 (p=0.01) and CYP4Z1 (p=0.01) showed correlations with tumour grade. CYP1B1 (p=0.001), CYP3A5 (p=0.001) and CYP51 (p=0.005) were the cytochrome P450s which showed the most significant correlations with oestrogen receptor status. Correlations with survival were identified for CYP2S1 (p=0.03), CYP3A4 (p=0.025), CYP4V2 (p=0.026) and CYP26A1 (p=0.03).
This study has defined the expression profile of cytochrome P450 in breast cancer and and may offer the potential application as biomarkers to aid decisions regarding optimal adjuvant therapy.
Original languageEnglish
Pages (from-to)202-211
Number of pages10
Issue number2
Publication statusPublished - Aug 2010


  • breast cancer
  • cytochrome P450
  • immunohistochemistry
  • prognosis
  • survival
  • tissue microarray


Dive into the research topics of 'Profiling the expression of cytochrome P450 in breast cancer'. Together they form a unique fingerprint.

Cite this